Phoenix, AZ, January 16, 2026 — Blue Genes (https://bluegeneslab.com), a personalized medicine company focused on pharmacogenetic (PGx) testing and genetic insights to support safer, more effective medication decisions, today announced the successful completion of its SOC 2 Type II examination as of January 16, 2025, covering the following scope:
Security, Availability, and Confidentiality of Blue Genes’ systems supporting its pharmacogenetic testing platform, data processing, and customer-facing applications.
The SOC 2 audit was conducted by A-LIGN, a leading provider of cybersecurity compliance services trusted by more than 4,000 global organizations to help mitigate cybersecurity risks.
“Completing our SOC 2 audit is an important milestone for Blue Genes and reinforces our commitment to protecting sensitive genetic and health-related data,” said Nick Glimcher, CEO of Blue Genes. “Data security and trust are foundational to personalized medicine, and this achievement reflects the rigor of our internal controls, policies, and operational practices.”
Established by the American Institute of Certified Public Accountants (AICPA), the SOC 2 examination is designed for organizations of any size, regardless of industry and scope, to ensure the personal assets of their potential and existing customers are protected. SOC 2 reports are recognized globally and affirm that a company’s infrastructure, software, people, data, policies, procedures, and operations have been formally reviewed.
“Congratulations to Blue Genes for completing their SOC 2 audit, a widely recognized signal of trust and security,” said Steve Simmons, COO of A-LIGN. “It’s great to work with organizations like Blue Genes, who understand the value of expertise in driving an efficient audit and the importance of a high-quality final report.”
This certification demonstrates Blue Genes’ continued commitment to compliance and provides customers, partners, and stakeholders with confidence that appropriate safeguards are in place to protect sensitive data.
